DX . DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Dx.doi.org Make Money
Keywords
Topics
Schema
External Links
Analytics And Tracking
Libraries
CDN Services

We began analyzing https://link.springer.com/article/10.1007/s10549-009-0502-2, but it redirected us to https://link.springer.com/article/10.1007/s10549-009-0502-2. The analysis below is for the second page.

Title[redir]:
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment | Breast Cancer Research and Treatment
Description:
Development of effective and durable breast cancer treatment strategies requires a mechanistic understanding of the influence of the microenvironment on response. Previous work has shown that cellular signaling pathways and cell morphology are dramatically influenced by three-dimensional (3D) cultures as opposed to traditional two-dimensional (2D) monolayers. Here, we compared 2D and 3D culture models to determine the impact of 3D architecture and extracellular matrix (ECM) on HER2 signaling and on the response of HER2-amplified breast cancer cell lines to the HER2-targeting agents Trastuzumab, Pertuzumab and Lapatinib. We show that the response of the HER2-amplified AU565, SKBR3 and HCC1569 cells to these anti-HER2 agents was highly dependent on whether the cells were cultured in 2D monolayer or 3D laminin-rich ECM gels. Inhibition of β1 integrin, a major cell–ECM receptor subunit, significantly increased the sensitivity of the HER2-amplified breast cancer cell lines to the humanized monoclonal antibodies Trastuzumab and Pertuzumab when grown in a 3D environment. Finally, in the absence of inhibitors, 3D cultures had substantial impact on HER2 downstream signaling and induced a switch between PI3K-AKT- and RAS-MAPK-pathway activation in all cell lines studied, including cells lacking HER2 amplification and overexpression. Our data provide direct evidence that breast cancer cells are able to rapidly adapt to different environments and signaling cues by activating alternative pathways that regulate proliferation and cell survival, events that may play a significant role in the acquisition of resistance to targeted therapies.

Matching Content Categories {📚}

Science
Education
Telecommunications

Content Management System {📝}

What CMS is dx.doi.org built with?

Custom-built

No common CMS systems were detected on Dx.doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of dx.doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Dx.doi.org Make Money? {💸}

We don't see any clear sign of profit-making.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Dx.doi.org might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

article, cancer, google, scholar, pubmed, cas, breast, cell, bissell, cells, biol, signaling, mammary, research, human, epithelial, threedimensional, response, culture, lines, trastuzumab, integrin, tissue, park, matrix, growth, activation, microenvironment, weigelt, petersen, normal, malignant, weaver, res, privacy, cookies, function, content, gray, cultures, extracellular, receptor, resistance, access, wang, tumor, lee, national, essential, data,

Topics {✒️}

month download article/chapter her2-negative breast cancer erbb signalling network cellular signaling pathways barcellos-hoff mh ras-mapk-pathway activation beta4 integrin-dependent formation her2-targeting agents trastuzumab human breast cancer her2 downstream signaling cell lines studied her2-amplified au565 human breast cells 3d culture models human cancer cells breast cancer cells dimensional culture models full article pdf her2-targeting agents anti-her2 agents privacy choices/manage cookies breast epithelial function mammary epithelial cells her2-positive drug-responsiveness rapidly distinguish growth integrin blocking antibodies breast cancer progression pten activation contributes dimensional culture assay transgenic mouse model mammary cell function cell lines reconstituted basement membrane basement membrane serves de-ac02-05ch1123 article weigelt mammary tumor induction dutch cancer society american cancer society her2 signaling targeted therapies check access instant access cell culture malignant mammary epithelium beta1-integrin activating alternative pathways integrin signaling regulate tumor induction

Schema {🗺️}

WebPage:
      mainEntity:
         headline:HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
         description:Development of effective and durable breast cancer treatment strategies requires a mechanistic understanding of the influence of the microenvironment on response. Previous work has shown that cellular signaling pathways and cell morphology are dramatically influenced by three-dimensional (3D) cultures as opposed to traditional two-dimensional (2D) monolayers. Here, we compared 2D and 3D culture models to determine the impact of 3D architecture and extracellular matrix (ECM) on HER2 signaling and on the response of HER2-amplified breast cancer cell lines to the HER2-targeting agents Trastuzumab, Pertuzumab and Lapatinib. We show that the response of the HER2-amplified AU565, SKBR3 and HCC1569 cells to these anti-HER2 agents was highly dependent on whether the cells were cultured in 2D monolayer or 3D laminin-rich ECM gels. Inhibition of β1 integrin, a major cell–ECM receptor subunit, significantly increased the sensitivity of the HER2-amplified breast cancer cell lines to the humanized monoclonal antibodies Trastuzumab and Pertuzumab when grown in a 3D environment. Finally, in the absence of inhibitors, 3D cultures had substantial impact on HER2 downstream signaling and induced a switch between PI3K-AKT- and RAS-MAPK-pathway activation in all cell lines studied, including cells lacking HER2 amplification and overexpression. Our data provide direct evidence that breast cancer cells are able to rapidly adapt to different environments and signaling cues by activating alternative pathways that regulate proliferation and cell survival, events that may play a significant role in the acquisition of resistance to targeted therapies.
         datePublished:2009-08-22T00:00:00Z
         dateModified:2009-08-22T00:00:00Z
         pageStart:35
         pageEnd:43
         sameAs:https://doi.org/10.1007/s10549-009-0502-2
         keywords:
            Breast cancer cell lines
            Drug response
            Targeted therapy
            3D cell culture
            HER2 signaling
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0502-2/MediaObjects/10549_2009_502_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0502-2/MediaObjects/10549_2009_502_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0502-2/MediaObjects/10549_2009_502_Fig3_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:122
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Britta Weigelt
               affiliation:
                     name:University of California Berkeley
                     address:
                        name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
                        type:PostalAddress
                     type:Organization
                     name:Cancer Research UK London Research Institute
                     address:
                        name:Cancer Research UK London Research Institute, London, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Alvin T. Lo
               affiliation:
                     name:University of California Berkeley
                     address:
                        name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Catherine C. Park
               affiliation:
                     name:University of California Comprehensive Cancer Center
                     address:
                        name:Department of Radiation Oncology, University of California Comprehensive Cancer Center, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Joe W. Gray
               affiliation:
                     name:University of California Berkeley
                     address:
                        name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mina J. Bissell
               affiliation:
                     name:University of California Berkeley
                     address:
                        name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
      description:Development of effective and durable breast cancer treatment strategies requires a mechanistic understanding of the influence of the microenvironment on response. Previous work has shown that cellular signaling pathways and cell morphology are dramatically influenced by three-dimensional (3D) cultures as opposed to traditional two-dimensional (2D) monolayers. Here, we compared 2D and 3D culture models to determine the impact of 3D architecture and extracellular matrix (ECM) on HER2 signaling and on the response of HER2-amplified breast cancer cell lines to the HER2-targeting agents Trastuzumab, Pertuzumab and Lapatinib. We show that the response of the HER2-amplified AU565, SKBR3 and HCC1569 cells to these anti-HER2 agents was highly dependent on whether the cells were cultured in 2D monolayer or 3D laminin-rich ECM gels. Inhibition of β1 integrin, a major cell–ECM receptor subunit, significantly increased the sensitivity of the HER2-amplified breast cancer cell lines to the humanized monoclonal antibodies Trastuzumab and Pertuzumab when grown in a 3D environment. Finally, in the absence of inhibitors, 3D cultures had substantial impact on HER2 downstream signaling and induced a switch between PI3K-AKT- and RAS-MAPK-pathway activation in all cell lines studied, including cells lacking HER2 amplification and overexpression. Our data provide direct evidence that breast cancer cells are able to rapidly adapt to different environments and signaling cues by activating alternative pathways that regulate proliferation and cell survival, events that may play a significant role in the acquisition of resistance to targeted therapies.
      datePublished:2009-08-22T00:00:00Z
      dateModified:2009-08-22T00:00:00Z
      pageStart:35
      pageEnd:43
      sameAs:https://doi.org/10.1007/s10549-009-0502-2
      keywords:
         Breast cancer cell lines
         Drug response
         Targeted therapy
         3D cell culture
         HER2 signaling
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0502-2/MediaObjects/10549_2009_502_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0502-2/MediaObjects/10549_2009_502_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0502-2/MediaObjects/10549_2009_502_Fig3_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:122
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Britta Weigelt
            affiliation:
                  name:University of California Berkeley
                  address:
                     name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
                     type:PostalAddress
                  type:Organization
                  name:Cancer Research UK London Research Institute
                  address:
                     name:Cancer Research UK London Research Institute, London, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Alvin T. Lo
            affiliation:
                  name:University of California Berkeley
                  address:
                     name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Catherine C. Park
            affiliation:
                  name:University of California Comprehensive Cancer Center
                  address:
                     name:Department of Radiation Oncology, University of California Comprehensive Cancer Center, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Joe W. Gray
            affiliation:
                  name:University of California Berkeley
                  address:
                     name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mina J. Bissell
            affiliation:
                  name:University of California Berkeley
                  address:
                     name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:122
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of California Berkeley
      address:
         name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
         type:PostalAddress
      name:Cancer Research UK London Research Institute
      address:
         name:Cancer Research UK London Research Institute, London, UK
         type:PostalAddress
      name:University of California Berkeley
      address:
         name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
         type:PostalAddress
      name:University of California Comprehensive Cancer Center
      address:
         name:Department of Radiation Oncology, University of California Comprehensive Cancer Center, San Francisco, USA
         type:PostalAddress
      name:University of California Berkeley
      address:
         name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
         type:PostalAddress
      name:University of California Berkeley
      address:
         name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Britta Weigelt
      affiliation:
            name:University of California Berkeley
            address:
               name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
               type:PostalAddress
            type:Organization
            name:Cancer Research UK London Research Institute
            address:
               name:Cancer Research UK London Research Institute, London, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Alvin T. Lo
      affiliation:
            name:University of California Berkeley
            address:
               name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
               type:PostalAddress
            type:Organization
      name:Catherine C. Park
      affiliation:
            name:University of California Comprehensive Cancer Center
            address:
               name:Department of Radiation Oncology, University of California Comprehensive Cancer Center, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Joe W. Gray
      affiliation:
            name:University of California Berkeley
            address:
               name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
               type:PostalAddress
            type:Organization
      name:Mina J. Bissell
      affiliation:
            name:University of California Berkeley
            address:
               name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
      name:Cancer Research UK London Research Institute, London, UK
      name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
      name:Department of Radiation Oncology, University of California Comprehensive Cancer Center, San Francisco, USA
      name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
      name:Life Sciences Division, Lawrence Berkeley National Laboratory, University of California Berkeley, Berkeley, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(235)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.47s.